Organization · Venture Capital
MPM BioImpact
MPM BioImpact is a biotechnology investment firm based in the United States, focusing on building and investing in innovative companies across all stages of drug development. They manage over $3 billion in assets and aim to deliver transformative therapies to patients.
Overview
What MPM BioImpact does
What MPM BioImpact is
MPM BioImpact is a biotechnology investment firm based in the United States, focusing on building and investing in innovative companies across all stages of drug development. They manage over $3 billion in assets and aim to deliver transformative therapies to patients.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Structured capabilities
- Funder
- Last reviewed
- March 18, 2026
Official channels
Find MPM BioImpact elsewhere
Open the official website or a supported primary organization account.
Capability profile
MPM BioImpact as a funder
Investment thesis
MPM BioImpact focuses on building and investing in innovative biotechnology companies across all stages of drug development, aiming to deliver transformative therapies to patients.
Focus narrative
MPM BioImpact invests in both private and public companies involved in the drug development process. Their investment strategy emphasizes transformative therapies for patients suffering from serious diseases. The firm employs a unique investment approach known as the BIOIMPACT FUND™, which targets companies that aim to enhance patient outcomes through innovative solutions.
Value beyond capital
MPM BioImpact adds value to its portfolio companies by leveraging its extensive experience in biotechnology investment, providing strategic guidance, and facilitating connections within the industry to enhance growth and development.
Focus and fit
- Stages
- Friends and Family · Angel · Accelerator · Pre-seed · Seed · Seed+ · Series A · Series A+ · Series B · Series B+ · Series C · Series C+ · Series D · Series E · Series F · Growth Equity · Pre-IPO · Ipo
- Regions
- United States
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 100
- Recorded notable exits
- IPO and M&A
Portfolio context
Notable portfolio companies include: Orna Therapeutics: Developing a new class of coding RNA medicines using circular RNA technology. Aktis Oncology: Focused on alpha radio-pharmaceuticals for solid tumors, utilizing miniprotein actinium-conjugates. Reunion Neuroscience: Developing next-generation psychedelic-inspired pharmaceutical compounds for mental health disorders. argenx: Known for its lead drug VYVGART, addressing serious autoimmune diseases.
Common questions
What to know about MPM BioImpact
Upseed classifies MPM BioImpact under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 18, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.